Adam Kroetsch | Clinical Trial Abundance: What it Means, Why We Need It, and How We Get There

What this video covers

A video from Foresight Institute, posted on Sep 23, 2026. It is about the science of aging.

It comes from a research institute, foundation or scientific meeting on aging. We link to it; we don't make or endorse it. Research stages on this site come from published studies, not from videos.

The science of aging: the research →

From the video's description

*Subscribe to Foresight Longevity Biotechnology Seminar Group:* https://foresight.org/seminar/longevity-biotechnology-seminar-group/ Supporting scientists, entrepreneurs, funders, and institutional partners in advancing biotechnology to reverse aging, extend human healthspan, and improve the human condition. This group is sponsored by 100 Plus Capital. http://100pluscap.com/ *Adam Kroetsch | Clinical Trial Abundance: What it Means, Why We Need It, and How We Get There* Abstract: In recent decades, drug discovery has been transformed by scientific advances, including AI. But increasingly, our ability to design drugs and generate hypotheses is outpacing our ability to test them. Clinical trials have become the critical bottleneck to medical advances. That's why we are advocating for clinical trial abundance: a focus on making clinical trials cheaper, faster, and more abundant - and more c…

Written by Foresight Institute on YouTube.

More videos like this

Research instituteARDD · Oct 29, 2026Kejun (Albert) Ying at ARDD2026: An open world model for human health and mortalityThe science of agingResearch instituteARDD · Oct 29, 2026Hao Pei at ARDD2026: Aging Is Multidimensional — So Must Be the DataThe science of agingResearch instituteARDD · Oct 29, 2026Yuancheng (Ryan) Lu at ARDD2026: Functional Genomics and Virtual ScreeningThe science of agingResearch instituteARDD · Oct 28, 2026Capital Markets and Philanthropy Panel at ARDD2026: What does AI in Longevity Biotech really need?The science of aging